Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire disorder (HSDD)—had no dedicated treatment option available to them. But that changed on December 15, 2025, when the FDA expanded its approval for the prescription drug Addyi (flibanserin), which was approved in 2015 to treat HSDD in premenopausal
5 min read WHEN THE JUSTICE Department released a trove of Epstein-related files on January 30 and then pulled down thousands of pages after redaction failures exposed victims’ identifying information and explicit material, I felt a familiar gut-drop. Once again, the people with the least power were being asked to pay twice—first for the abuse
You don't have permission to access "http://www.medpagetoday.com/obgyn/hrt/119940" on this server. Reference #18.5bf4d517.1771491743.1e0de1 https://errors.edgesuite.net/18.5bf4d517.1771491743.1e0de1
It’s the rare policy question that unites Republican Gov. Ron DeSantis of Florida and the Democratic-led Maryland government against President Donald Trump and Gov. Gavin Newsom of California: How should health insurers use AI? Regulating artificial intelligence, especially its use by health insurers, is becoming a politically divisive topic, and it’s scrambling traditional partisan lines.